Advanced High Throughput Screening Tools to Enter British Biotech Market

Cambio (Cambridge, United Kingdom) will now be supplying its local and international customers with BellBrook Labs’ (Madison WI, USA) Transcreener HTS Assays and iuvo Microconduit array technology.

Cambio is a privately held British company with a reputation for supplying high quality molecular biology reagents and consumables. To meet the needs of a growing and diversifying market, advanced molecular biology products are continually being added to the company’s portfolio.

BellBrook Labs’ Transcreener Biochemical Assay Platform was developed to move more new targets into the realm of high throughput assays and to streamline selectivity profiling within a target family. It relies on the homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, GDP, AMP, and GMP, which are formed by thousands of cellular enzymes. Among these are group transferase families, such as kinases and glycosyltransferases that catalyze the covalent regulatory reactions that are central to cell signaling. Each Transcreener Assay provides a generic detection method for multiple enzyme families. This promotes the evaluation of new therapeutic strategies and optimization of lead molecules and reduces time-consuming assay development for individual targets.

Cambio also will be marketing BellBrook Labs’ iuvo MicroConduit Array Technology. These microscale cell-culture devices incorporate unique advantages for miniaturization and automation of cellular assays. MicroConduit Arrays rely on liquid displacement from microchannels rather than the cumbersome aspiration and replacement used with open wells, yet they are compatible with existing liquid dispensing equipment. Applications include invasion and migration assays and reconstruction of cells in complex three-dimensional formats that recapitulate paracrine signaling in the context of native tissue.

Related Links:
Cambio
BellBrook Labs